Active Studies

We are constantly seeking participants for a number of studies. Please apply to any studies for which you may qualify, or call us at (417) 883-7889 for more information!

    Migraine Study

    GM-US-10

    This study consists of 5 in-person visits and 1 phone call over 16 weeks. Qualified people who report 8-20 headaches per month will be randomized to use non-invasive vagus nerve stimulation delivered through an investigational device 3 times a day during a 12-week treatment phase.  Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide the study device and all study-related procedures at no cost to you. You would be asked to use an electronic diary to answer daily questions about your headaches for the entire duration of the study. You would also be asked to fill out more detailed questionnaires during the appointments. Compensation will be provided for your time and travel.

    Migraine Research Study

    BHV3000-305

    Qualified subjects will be randomized to take a pill every other day for 12 weeks, either active or placebo followed by an additional 12 weeks of receiving active product. This study has 12 visits and is 30 weeks in duration. Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide an investigational study pill and all study-related procedures at no cost to you (including basic study-related physical exams, bloodwork, ECG’s, and urine drug/pregnancy tests). You would be asked to use a handheld electronic diary to answer daily questions about your headaches for the entire duration of the study. You would also be asked to fill out more detailed questionnaires during the appointments. Compensation will be provided for your time and travel.

    Ankylosing Spondylitis

    CAIN457FUS06

    The purpose of this study is to determine the benefit of taking 300mg of an investigational drug compared to the currently approved 150mg dose for patients with Ankylosing Spondylitis (AS). Qualifying volunteers would come to our office for approximately 19 visits over a 52-week period. Patients will be given 16 doses of the investigational drug during the course of the study.

    Post Traumatic Headaches

    TV48125-CNS-20024

    This research study is to compare the duration, safety, and effectiveness of the investigational study medication (Fremanezumab) to placebo (an inactive look-alike). Qualified volunteers will be randomly assigned to receive study medication or placebo. Completion of the study would involve coming to our office for 7 appointments, over a 44-week period. Subjects will receive 3 doses of investigational product or placebo during the study.

    Psoriatic Arthritis

    Abbvie M15-572

    The study is for subjects 18 and older. The study duration is up to 3 years. Subject will receive both oral study drug once daily and subcutaneous study drug every other week. Period 1 is 56 weeks and 13 site visits. Subject will have a site visit at week 56 and every 12 weeks thereafter.

    Psoriatic Arthritis

    Abbvie M15-554

    The research study is available for participants 18 and older. The subject will take the study drug once daily. There are 13 office visits in Period 1. The study duration is up to 3 years. Subject will have a study visit at week 56 and every 12 weeks thereafter.

    Rheumatoid Arthritis Prevention

    Abbvie M15-925

    Clinvest Research is currently enrolling participants for a phase 3 clinical study investigating a new selective JAK1 inhibitor for Rheumatoid Arthritis. Participants need to be over 18 years of age, have diagnosis of Rheumatoid Arthritis, have had an inadequate response or intolerant to previous treatments, and on a stable dose of a Synthetic Disease Modifying Anti-Rheumatic Drug. The study is up to 5 years in duration. Compensation for time and travel may be provided and study related care is at no cost.

    Chronic Migraine Prevention

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine.